Moffitt Cancer Center | Strategic Alliance Partners

October 24, 2023

Danielle K. DePalo, MD, explains the lack of research directly comparing first-line treatment options for patients with unresectable melanoma in-transit metastases, expands on the safety and efficacy of 3 treatment modalities for these patients, and underscores the need for more data to inform the management of these patients.

October 21, 2023

Andrew Kuykendall, MD, discusses frontline cytoreductive treatment options for patients with polycythemia vera.

October 16, 2023

Dr Kuykendall discusses the FDA approval of momelotinib in myelofibrosis with anemia, key data from the MOMENTUM trial, and how momelotinib alters the myelofibrosis treatment paradigm.

October 12, 2023

Rami Komrokji, MD, provides clinical insights on treatment decision-making, sequencing, and combinations for patients with myelodysplastic syndrome. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

October 12, 2023

Valeria Santini, MD, reviews data from real-world outcomes in clinical trials investigating luspatercept in patients with lower-risk MDS.

October 05, 2023

Expert perspectives on the clinical implications of recent clinical trial data on new therapies in lower-risk myelodysplastic syndrome.

October 05, 2023

The panel of experts review recent data updates for new agents being investigated in the second line in patients with lower-risk MDS.

September 28, 2023

Uwe Platzbecker, MD, reviews data updates from the MEDALIST trial investigating luspatercept in patients with lower-risk myelodysplastic syndrome.

September 28, 2023

Comprehensive insights on the differences and similarities in treatment algorithms for physicians treating patients with MDS in and outside the United States. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

September 27, 2023

Tiago Biachi, MD, PhD, discusses the growing treatment landscape for patients with hepatocellular carcinoma.

September 22, 2023

Key opinion leaders Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, consider the evolving treatment landscape of follicular lymphoma and look toward future evolutions in the field.

September 22, 2023

Centering discussion on a second patient scenario of follicular lymphoma, key opinion leaders consider best therapy for patients with early or aggressive relapse.

September 21, 2023

The expert panel reviews updated data from the COMMANDS trial on luspatercept in patients with lower-risk MDS and discusses their effect on clinical practice. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

September 21, 2023

A panel of expert hematologists give an overview of myelodysplastic syndrome, focusing on diagnosis, classification, and treatment practices.

September 15, 2023

Andrew Kuykendall, MD, discusses the significance of the FDA approval of momelotinib in patients with myelofibrosis.

September 15, 2023

A brief discussion on the respective roles of EZH2- and PI3K-targeted therapies in patients with relapsed/refractory follicular lymphoma.

September 15, 2023

Switching focus back to relapsed/refractory follicular lymphoma, Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, consider the list of available treatment options in this setting.

September 12, 2023

Hagop M. Kantarjian, MD, and Bijal D. Shah, MD, MS, delve into upcoming strategies for handling Philadelphia-chromosome positive acute lymphoblastic leukemia, considering recent breakthroughs.

September 12, 2023

Insights on real-world ponatinib treatment strategies and safety in Philadelphia-positive acute lymphoblastic leukemia are provided by Hagop Kantarjian, MD, and Bijal D. Shah, MD, MS.

September 08, 2023

Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, review the frontline treatment armamentarium available to patients with follicular lymphoma.